Acrux Secures AU$1.5 Million Funding Facility; Shares Fall 3%

Acrux (ASX:ACR) secured a AU$1.5 million funding facility with a monthly interest of 1.33% with Radium Capital. The short-term facility will be repaid later in 2024. It is secured against the specialt

MT NewswiresJun 27 22:19 ET

Percheron Therapeutics Appoints CFO

Percheron Therapeutics (ASX:PER) appointed Deborah Ambrosini as its chief financial officer and company secretary, effective immediately, according to a Monday filing with the Australian bourse. Ambro

MT NewswiresJun 16 20:04 ET

Acrux, TruPharma Launch Dapsone 5% Gel in US

Pharmaceutical company Acrux (ASX:ACR) and its partner TruPharma introduced a generic version of the topical prescription medication Dapsone 5% Gel in the US, according to a Wednesday filing with the

MT NewswiresApr 2 20:33 ET

Acrux Gets AU$3 Million Tax Rebate for Fiscal Year 2023

Acrux (ASX:ACR) received a rebate worth AU$2.9 million for the fiscal year ended June 30 as part of the Australian government's research and development tax incentive scheme. The scheme aims to encour

MT NewswiresNov 7, 2023 23:19 ET

US FDA Approves Review of Acrux (ASX:ACR) Nitroglycerin Ointment

The Market HeraldJul 3, 2023 22:59 ET

Acrux Limited (ASX:ACR) Insider Purchases A$91,665.00 in Stock

Acrux Limited (ASX:ACR – Get Rating) insider Donald Brumley bought 1,455,000 shares of the business's stock in a transaction dated Thursday, March 9th. The shares were purchased at an average cost of

Defense WorldMar 13, 2023 05:53 ET